about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

Last year
R&D

Deer­field taps NYU Lan­gone Health as lat­est aca­d­e­m­ic part­ner, ink­ing $130M trans­la­tion­al re­search pact

Last year
Deals
Discovery

Bay­er gets its hands on Acuitas' LNP as it lines up first shots at gene edit­ing

Last year
Deals
Cell/Gene Tx

Ital­ian AAV biotech clos­es $65M Se­ries A; GSK's Jem­per­li nabs pri­or­i­ty re­view in en­dome­tri­al can­cer

Last year
News Briefing

No­vo Hold­ings, Gur­net Point Cap­i­tal en­gi­neer $462M take-pri­vate deal for an­tibi­otics play­er Paratek

Last year
Deals

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Last year
R&D

Bellerophon's stock tanks as in­haled drug-de­vice fails to re­deem it­self in new PhI­II af­ter pre­vi­ous flops

Last year
R&D

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

Last year
Deals

Roger Perl­mut­ter lines up deals, fresh fund­ing at Eikon; Sec­ond RSV vac­cine ap­proved; Sev­er­al biotechs flash­ing red; ...

Last year
Weekly

On­corus lays off most of its re­main­ing team, warns of wind-down as it takes one last shot at deal­mak­ing

Last year
People

Lon­za shells out $107M cash to snap up Synaf­fix and its ADC plat­form

Last year
Deals
Manufacturing

As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

Last year
R&D

Clin­i­cal hold for Pep­Gen's my­oton­ic dy­s­tro­phy pro­gram halts march to the clin­ic

Last year
FDA+

Ake­bia to re­file ane­mia drug vadadu­s­tat af­ter FDA de­nied ap­peal

Last year
R&D

On­copep­tides says Swedish au­thor­i­ties end­ed probe in­to CSO Jakob Lind­berg over al­leged in­sid­er in­for­ma­tion shar­ing

Last year
People
Law

End­points 20(+2) un­der 40, 2023; Bio­phar­ma's high­est-paid CEOs; N-of-1 CRISPR sto­ry goes on af­ter tragedy; and more

Last year
Weekly

Cor­rect­ed: Bench­Sci rais­es $70M Se­ries D for drug dis­cov­ery soft­ware; Zen­tal­is touts PhIb ovar­i­an can­cer da­ta

Last year
News Briefing

Benev­o­len­tAI lays off around 180 staffers, cuts pipeline pro­grams in re­org

Last year
People

Dutch biotech rais­es €30M for up­scaled man­u­fac­tur­ing, pi­lot study of blood clot­ting drug

Last year
Financing

En­ta­sis lands first an­tibi­ot­ic ap­proval eight years af­ter spin­ning out of As­traZeneca

Last year
R&D

PTC cuts gene ther­a­py pro­grams, dis­clos­es PhI­II fail in Friedre­ich's atax­ia and CFO ex­it

Last year
R&D
Cell/Gene Tx

PhI­II win for smok­ing ces­sa­tion treat­ment puts Achieve Life Sci­ences on path to FDA, jazzes up deal talks

Last year
R&D

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

Last year
Startups
Cell/Gene Tx

Alex­ion touts ear­ly 'proof-of-con­cep­t' da­ta for Neurim­mune an­ti­body in AT­TR car­diomy­opa­thy

Last year
R&D
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times